Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported Long Term Debt of $100.89 million for the year ending 2025.
- RHYTHM PHARMACEUTICALS, INC. showed a decrease of -6.8% in Long Term Debt from 2024 to 2025.
- This data is from RHYTHM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $34.27 million | Q3 2022: $72.96 million | Q1 2025: $107.93 million | Q2 2025: $106.01 million | Q3 2025: $103.41 million.
- Over the full 3 years of available data (2023 to 2025), RHYTHM PHARMACEUTICALS, INC.'s Long Term Debt has declined by 5.0%.
- Historical annual values: Fiscal year 2025: $100.89 million | Fiscal year 2024: $108.27 million | Fiscal year 2023: $106.14 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: